Biogen finalizes $900M settlement in false claims whistleblower suit
By 
Adrianne Appel2022-09-27T19:04:00
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors, the Department of Justice (DOJ) announced Monday.
Biogen made the alleged payments to try and dampen competition for its multiple sclerosis (MS) drugs, including Avonex, Tysabri, and Tecfidera, according to the settlement.
The agreement, first disclosed by Biogen in July, ends years of litigation dating back to 2012, when former employee Michael Bawduniak blew the whistle on the alleged kickbacks. He filed a lawsuit against the company in U.S. District Court for the District of Massachusetts, citing violations of the False Claims Act (FCA).
Related articles
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
-
ArticlePhilips to pay $1.3M in second kickback settlement in month
Philips RS North America agreed to pay approximately $1.3 million to settle charges it unlawfully paid kickbacks as part of its second resolution addressing alleged False Claims Act violations this month.
-
ArticleEssilor agrees to $22M settlement over kickback charges
Essilor, a manufacturer and distributor of optical lenses and equipment, will pay $22 million to settle allegations it paid kickbacks to spur sales in violation of the False Claims Act.
More from Regulatory Enforcement
-
ArticleCrypto firms brace for tighter UK oversight as FCA plots integration with financial markets
Trying to put rules in place to oversee an industry that has grown largely outside of regulation is not without serious challenges. But the UK’s Financial Conduct Authority’s (FCA) latest consultation aims to attract industry views about how some key aspects of crypto trading should be regulated ahead of planned ...
-
ArticleSeven years in, GDPR faces growing challenges from AI and ‘consent or pay’ models
Europe’s pioneering data protection legislation turned seven years old in May, but the compliance and enforcement difficulties that have dogged the rules since they came into force look set to present both companies and data regulators with fresh headaches for some time to come.
-
News BriefDOJ charges crypto executive with laundering $530M for sanctioned Russian banks
The Department of Justice has charged the founder of cryptocurrency company Evita with 22 violations for allegedly laundering more than $500 million through U.S. banks and cryptocurrency exchanges, on behalf of sanctioned Russian entities.